Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2025 09:23 ET | Source: Research and Markets

Opdivo (nivolumab) Market Research Report 2025: Rising NSCLC Prevalence and Immunotherapy Acceptance Fueling Growth - Forecasts to 2034

Dublin, May 14, 2025 (GLOBE NEWSWIRE) -- The "Opdivo (nivolumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's...
October 09, 2020 04:24 ET | Source: Research and Markets

Global Programmed Death-Ligand 1 (PD-L1) Non-Small Cell Lung Cancer (NSCLC) Market Insights, Epidemiology and Market Forecast 20202030

Dublin, Oct. 09, 2020 (GLOBE NEWSWIRE) -- The "Programmed Death-Ligand 1 (PD-L1) Non-Small Cell Lung Cancer (NSCLC)-Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been...
June 02, 2020 08:15 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Preliminary Data From and Planned Continuation of the ILLUMINATE-206 Trial for the Treatment of Micro-Satellite Stable Colorectal Cancer

EXTON, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today announced preliminary data from the first 10 patients in the safety cohort of ...
September 11, 2019 07:30 ET | Source: Momotaro-Gene

Momotaro-Gene Announces First Patient Dosed in Phase 2 Clinical Trial of MTG201 in Combination with Nivolumab in Patients with Relapsed Malignant Pleural Mesothelioma

OKAYAMA, Japan, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Momotaro-Gene, a clinical-stage biotherapeutics company developing novel gene therapies for the treatment of cancer, today announced the dosing of...
June 01, 2018 16:11 ET | Source: OmniSeq

OmniSeq and LabCorp Launch OmniSeq Advance℠ Assay

CHICAGO, June 01, 2018 (GLOBE NEWSWIRE) -- ASCO – OmniSeq®, a CAP-accredited, molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE:LH), a leading...
June 14, 2017 08:05 ET | Source: OmniSeq

OmniSeq Launches Immune Report Card

BUFFALO, N.Y., June 14, 2017 (GLOBE NEWSWIRE) -- OmniSeq, an innovation of Roswell Park Cancer Institute, announced today the commercial launch of Immune Report Card SM, the first immune profiling...